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founders (disease duration, age, education and concomitant dis- 
eases). 
Results: Mean (SD) age in the OA/RA groups was 61.6 
(5.6)/61.1 (6.0) years. Pain measures were numerically worse 
in OA than in RA and showed a statistically significant differ- 
ence for 2 (AIMS2 and SF 36) out of the 3 pain measures 
(table, two-sample t-test). Further levels of mental health sta- 
tus and fibromyalgia-like symptoms were also worse in OA than 
RA. Physical health status was significantly better in OA than 
RA,while social functioning, self-efficacy and utility were similar 
(data not shown). 
Conclusions: Female patients with hand OA experience more 
pain, more fibromyalgia-like symptoms and poorer mental health 
than women with RA of the same age. Our results point toward a 
difference between these two groups regarding the presence of 
soft tissue symptoms and/or that neuromuscular factors can have 
a different impact on pain perception in OA and RA patients. 
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Objectives: The primary aim of the present study was to test 
if a herbal remedy made from a subspecies of rose hip (Rosa 
canina) might reduce symptoms of osteoarthritis after short time 
of treatment (3 weeks). Secondary efficacy variable was lipid 
metabolism. 
Methods: Ninety four patients with osteoarthritis of the hip or 
knee were enrolled in a randomized, placebo-controlled, double 
blind cross-over trial. 
Treatment: Forty seven patients were given five grams of the 
herbal remedy daily for a period of three months and the remain- 
ing patients were given a similar amount of identical placebo. The 
group initially treated with placebo was then changed to rose hip 
and vice versa for another three months period. Upon inclusion 
and after 3 weeks and 3 months of each treatment period pain, 
stiffness, disability and global severity of the disease was esti- 
mated on a WOMAC questionnaire. Cholesterol levels were esti- 
mated in the beginning and at the end of each treatment periods. 
Data were analyzed on the basis of intention to treat. 
Results: WOMAC pain significantly declined (p<0.02) as com- 
pared to placebo, when testing after 3 weeks of treatment. 
WOMAC disability, stiffness and global assessment of severity 
of the disease significantly declined after three months treatment 
(p< 0.04). In addition three months treatment resulted in a signif- 
icant decline in cholesterol (p<0.05). 
Conclusion: The present data suggest that the herbal remedy 
rose hip can alleviate symptoms of osteoarthritis in three weeks. 
The reduction in cholesterol can be related to treatment or is pos- 
sibly the result of enhanced physical activity caused by the reduc- 
tion of symptoms. 
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Rationale: Viscosupplementation by repeated intra-articular (IA) 
injections of hyaluronic acid (HA) is widely used in the treatment 
of knee osteoarthritis (OA). In some cases the number of injec- 
tions can be a limitating factor for the treatment. 
Aim: To assess different dosing regimens of hylan G-F 20, a high 
molecular-weight cross-linked derivative of HA, in the treatment 
of symptomatic knee OA. 
Methods: Prospective, multi-centre, open-label, randomised trial, 
including 100 patients (56 F, 44 M), aged 40 yrs or older (mean 
61.1, range 41-86), with unilateral symptomatic tibio-femoral OA 
(Kellgren-Lawrence grade II - III) who were randomised to 5 
groups to receive hylan G-F 20 IA injection of either 1 x 6 mL, 
1 x 4 mL, 2 x 4 mL 2 weeks apart, 3 x 4 mL 1 week apart, or 3 
x 2 mL 1 week apart. Target knee and systemic adverse events 
(AEs) were monitored throughout he study. Safety was also as- 
sessed by the patient using a 4-point side-effect rating scale. The 
primary endpoint for efficacy was a patient rated knee OA pain 
assessment using a 100mm VAS at 24 weeks following the first 
injection as compared to baseline. The secondary endpoints in- 
cluded WOMAC, patient and physician global assessments and 
knee OA pain assessment at all visits. Concomitant use of per- 
mitted rescue medications (paracetamol) was also assessed. The 
statistical analyses were performed on the ITT population. 
Results: All demographic parameters were similarly distributed 
between the 5 treatment groups. 
Safety: There were no serious device-related AEs.The safety pro- 
file of all treatment groups was relatively similar (pain, swelling, ef- 
fusion). Group 4 (3x4 mL) had the highest percentage of device- 
related local AEs (30%) whereas group 1 ( lx6  mL) and group 5 
(3x2 mL) had only 15%. 
Efficacy: There was a statistically significant improvement from 
baseline to week 24 in all endpoints for all treatment regimens. 
The study was not powered for statistical differences in efficacy 
between groups. However the groups 1, 4 and 5 consistently 
showed the greatest mean improvement. Table I summarizes the 
rankings of mean response to treatment for the primary and sec- 
ondary endpoints by treatment group. Notably, group 1 is ranked 
either first or second for all listed endpoints. 
Table I 
1X6mL 1X4mL 2X4mL 3X4mL 3X2mL 
Pain 2 4 5 3 1 
Womac pain 2 5 4 1 3 
Womac function 2 4 5 1 3 
Patient assessment 1 5 4 2 3 
Physician assessment 1 5 4 3 2 
Conclusion: Treatment with hylan G-F 20 was well tolerated in 
all groups up to a total dose of 12 mL.This study suggests that a 
single 6mL injection could be an alternative to the currently ap- 
proved 3 x 2mL treatment regimen. A double blind controlled trial 
is in progress to confirm these data. 
